Bill Roth, IntegriChain

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

A look at the actionable steps needed to elicit change.

A crash course on the bubble itself, including therapeutic areas most affected.

Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

The trend is continuing for brands and even for some specialty products.

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

New PC column explores commercialization trends and how pharma can adjust to the new squeeze of market, regulatory, pricing, and gross-to-net pressures.